City Therapeutics (Nasdaq: CTY), a clinical-stage RNAi company, closed its upsized IPO raising $230M at $18 per share. Read ...
Disc Medicine's bitopertin met all primary and secondary endpoints in the Phase 3 APOLLO trial for EPP, setting up an NDA ...
Rapport Therapeutics' RAP-219 met primary and secondary endpoints in a Phase II bipolar mania trial, cutting YMRS scores. See results and Phase III plans.
FDA grants accelerated approval to GSK's Jemperli for stage II/III MSI-H or dMMR locally advanced rectal cancer. Read what this means for patients today.
Lilly's Omvoh met its Phase III primary endpoint in pediatric ulcerative colitis, with 50% of responders in remission at Week ...
Gilead's oral α4β7 integrin inhibitor emvistegrast met the primary endpoint in Phase II SWIFT study for ulcerative colitis.
AbbVie (NYSE: ABBV) reported that its investigational dual-targeting combination ABBV-466 achieved primary endpoints in ...
Evaxion's personalized cancer vaccine EVX-01 kept all Phase II melanoma patients in response at three years, with no tumor ...
Entrada's ENTR-601-45 met its Phase I/II safety endpoint at 5 mg/kg in DMD patients, showing modest dystrophin gains. Read ...
FDA approves Ryzumvi label expansion for presbyopia, giving Viatris' phentolamine eye drop a second indication. Read the full details and clinical impact.
Nouscom closes oversubscribed EUR 120M Series D to advance NOUS-209 toward a Lynch syndrome registration trial. Learn what this means for patients.
Betta pan-RAS inhibitor BPI-572270 wins NMPA combination trial acceptance in China, plus Australian and US FDA trial ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results